Shares of Lupin Ltd dropped 2.8% despite a significant Q3 profit increase of 38.8% year-on-year. The company's revenue surged 102.7%, reach...

Pharmaceuticals firm Lupin Ltd on Friday said it will fully acquire French pharmaceutical company Medisol for 18 million euros (over Rs 160...

Netflix Germany posted on Twitter that they had intended to reveal the release date for Lupine Part 3, but it seems someone else had other ...

A total of 36,555 shares changed hands on the counter till 01:28PM (IST)

Lupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 42717.22 Crore) operating in Pharmaceuticals s...

The pegfilgrastim filing is the company's first biosimilar filing in the US and is a milestone in the drug maker's research and innovation ...

Kyowa grew a modest 5% over the year-ago level. Its net profit halved to Rs 68.6 crore constituting 11.3% of Lupin’s consolidated profit. "...

The randomised trial of 52 weeks was conducted in 11 countries and included over 500 patients, Lupin said.

In this space, ETMarkets.com tracks the elite 30 from the Sensex pack and 50 from the nimble Nifty LIVE to help you understand why the mark...

The skin-focused pharma company, owned by a group of private equity investors, has asked investment bank NM Rothschild to help find a buyer...

A day after announcing its biggest acquisition deal of $880 million, Lupin today said it will buy Germany-based Temmler Pharma's specialty ...

After rising 1.91 % to Rs 1,851.15 in intra-day trade, shares of Lupin succumbed to profit-booking and finally ended at Rs 1,811.10.

The company has acquired 100 per cent equity stake in Medquimica Industria Farmaceutica subject to certain closing conditions.

Sales in the emerging market regions are one of the key growth drivers for Darmstadt-based Merck Serono, amounting to close to 1.8 billion ...

Lupin's Etanercept biosimilar, developed by its Biotechnology Research Group in Pune will be the first product to be licensed for clinical ...

Desh Bandhu Gupta built Lupin into a $1-billion enterprise, but he will chart the journey to $3 billion and beyond with his two children.

Lupin Pharma will launch a new branded generic drug in the US every year for specialised therapeutic areas.